PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Rupp, M. ; Ferry, T.* ; Khan Mirzaei, M. ; Alt, V.* ; Deng, L. ; Walter, N.

Bakteriophagen zur Behandlung muskuloskelettaler Infektionen – Eine Übersicht zu klinischem Einsatz, offenen Fragen und rechtlichem Rahmen.

Bacteriophages for the treatment of musculoskeletal infections-An overview of clinical use, open questions, and legal framework.

Orthopadie, DOI: 10.1007/s00132-025-04690-z (2025)
Verlagsversion DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
BACKGROUND: Bacteriophages, or simply phages, are viruses that specifically infect and lyse bacteria. As antibiotic resistance becomes a growing global concern, phage therapy is gaining renewed attention as a targeted and effective treatment option. In orthopedics and trauma surgery-disciplines characterized by high rates of chronic and implant-associated infections-phages offer promising new therapeutic avenues, particularly in cases involving multidrug-resistant pathogens or when conventional surgery is limited. CURRENT DEVELOPMENTS: Originally developed in the early 20th century, phage therapy lost prominence with the rise of antibiotics. Today, case studies and emerging clinical protocols-especially in the context of periprosthetic joint infections-demonstrate the potential of personalized phage cocktails and advanced delivery systems, such as hydrogels or intra-articular injections. Their specificity enables bacterial eradication while sparing the host microbiome. REGULATORY SITUATION: However, the regulatory landscape in the European Union poses significant challenges. Phages are classified as biological medicinal products, requiring comprehensive preclinical and clinical evaluation. While magistral production and compassionate use permit individual applications, broad clinical integration demands standardized protocols, accessible phage libraries, and robust quality control. Furthermore, safety concerns, including immunogenicity and systemic distribution, must be addressed through structured research. CONCLUSION: To fully realize the potential of phage therapy in orthopaedic infection management, interdisciplinary collaboration, targeted funding, and clinical trials are essential. Responsible implementation within expert centers can ensure efficacy and safety, paving the way for a controlled and evidence-based adoption of phages as a complementary strategy alongside traditional surgical and antibiotic treatments.
Impact Factor
Scopus SNIP
Altmetric
0.500
0.312
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Antibiotics ; Endoprosthesis ; Multidrug Resistance ; Periprosthetic Joint Infection ; Phage Therapy; Phage Therapy
Sprache deutsch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 2731-7145
e-ISSN 2731-7153
Zeitschrift Die Orthopädie
Verlag Springer
Verlagsort One New York Plaza, Suite 4600, New York, Ny, United States
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-554300-001
Förderungen Projekt DEAL
DOI 10.1007/s00132-025-04690-z
WOS ID 001542012200001
Scopus ID 105012280654
PubMed ID 40745494
Erfassungsdatum 2025-10-02
[➜Korrektur melden]